Predicting Visual Acuity by Using Machine Learning in Patients Treated for Neovascular Age-Related Macular Degeneration

被引:93
|
作者
Rohm, Markus [1 ,2 ]
Tresp, Volker [2 ]
Mueller, Michael [1 ]
Kern, Christoph [1 ]
Manakov, Ilja [1 ,2 ]
Weiss, Maximilian [1 ]
Sim, Dawn A. [3 ]
Priglinger, Siegfried [1 ]
Keane, Pearse A. [3 ]
Kortuem, Karsten [1 ,3 ]
机构
[1] Ludwig Maximilians Univ Munchen, Dept Ophthalmol, Munich, Germany
[2] Ludwig Maximilians Univ Munchen, Dept Comp Sci, Munich, Germany
[3] Moorfields Eye Hosp, London, England
关键词
INTRAVITREAL AFLIBERCEPT; DIABETIC-RETINOPATHY; RANIBIZUMAB; BEVACIZUMAB; OUTCOMES; EDEMA; PROGRESSION; TRIAL; EYE;
D O I
10.1016/j.ophtha.2017.12.034
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To predict, by using machine learning, visual acuity (VA) at 3 and 12 months in patients with neovascular age-related macular degeneration (AMD) after initial upload of 3 anti-vascular endothelial growth factor (VEGF) injections. Design: Database study. Participants: For the 3-month VA forecast, 653 patients (379 female) with 738 eyes and an average age of 74.1 years were included. The baseline VA before the first injection was 0.54 logarithm of the minimum angle of resolution (logMAR) (+/- 0.39). A total of 456 of these patients (270 female, 508 eyes, average age: 74.2 years) had sufficient follow-up data to be included for a 12-month VA prediction. The baseline VA before the first injection was 0.56 logMAR (+/- 0.42). Methods: Five different machine-learning algorithms (AdaBoost.R2, Gradient Boosting, Random Forests, Extremely Randomized Trees, and Lasso) were used to predict VA in patients with neovascular AMD after treatment with 3 anti-VEGF injections. Clinical data features came from a data warehouse (DW) containing electronic medical records (41 features, e.g., VA) and measurement features from OCT (124 features, e.g., central retinal thickness). The VA of patient eyes excluded from machine learning was predicted and compared with the ground truth, namely, the actual VA of these patients as recorded in the DW. Main Outcome Measures: Difference in logMAR VA after 3 and 12 months upload phase between prediction and ground truth as defined. Results: For the 3-month VA forecast, the difference between the prediction and ground truth was between 0.11 logMAR (5.5 letters) mean absolute error (MAE)/0.14 logMAR (7 letters) root mean square error (RMSE) and 0.18 logMAR (9 letters) MAE/0.2 logMAR (10 letters) RMSE. For the 12-month VA forecast, the difference between the prediction and ground truth was between 0.16 logMAR (8 letters) MAE/0.2 logMAR (10 letters) RMSE and 0.22 logMAR (11 letters) MAE/0.26 logMAR (13 letters) RMSE. The best performing algorithm was the Lasso protocol. Conclusions: Machine learning allowed VA to be predicted for 3 months with a comparable result to VA measurement reliability. For a forecast after 12 months of therapy, VA prediction may help to encourage patients adhering to intravitreal therapy. (C) 2018 by the American Academy of Ophthalmology
引用
收藏
页码:1028 / 1036
页数:9
相关论文
共 50 条
  • [21] Association Between Visit Adherence and Visual Acuity in Neovascular Age-Related Macular Degeneration
    Patel, Shriji
    Sternberg, Paul, Jr.
    JAMA OPHTHALMOLOGY, 2020, 138 (03) : 242 - 243
  • [22] Relationship between foveal birefringence and visual acuity in neovascular age-related macular degeneration
    Weber, A.
    Elsner, A. E.
    Miura, M.
    Kompa, S.
    Cheney, M. C.
    EYE, 2007, 21 (03) : 353 - 361
  • [23] Relationship between foveal birefringence and visual acuity in neovascular age-related macular degeneration
    A Weber
    A E Elsner
    M Miura
    S Kompa
    M C Cheney
    Eye, 2007, 21 : 353 - 361
  • [24] Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision
    Shona, Olajumoke
    Gupta, Bhaskar
    Vemala, Roopa
    Sivaprasad, Sobha
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2011, 39 (01): : 5 - 8
  • [25] Perfusion pressure correlates with visual acuity in patients with non-neovascular age-related macular degeneration
    Contreras, FM
    Harris, A
    Siesky, B
    Gao, H
    Danis, RP
    Rechtman, E
    McCranor, L
    Klaas, C
    Ciulla, TA
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
  • [26] Detecting conversion to exudative neovascular age-related macular degeneration using machine learning
    Zweifel, Sandrine
    Wiest, Maximilian
    Mislevics, Anton
    Peremot, Daryna
    Bondarenko, Andrey
    Fasler, Katrin
    Hamann, Timothy
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [27] Visual Acuity Outcomes of Fellow Eyes Treated for New Onset Neovascular Age-Related Macular Degeneration in Patients in the RENO study
    Mojumder, Nazrul
    Dang, Jonathan
    Khanani, Arshad M.
    Gahn, Greggory
    Koci, Micaela
    Phillips, Sylvia
    Hill, Lauren
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [28] Predicting Visual Acuity From Visual Field Sensitivity in Age-Related Macular Degeneration
    Denniss, Jonathan
    Baggaley, Helen C.
    Astle, Andrew T.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (11) : 4590 - 4597
  • [29] Long Term Visual Acuity And Macular Thickness in Patients With Neovascular Age-Related Macular Degeneration (NVAMD) treated with anti-VEGF Therapy
    Parlitsis, George J.
    Rezaei, Kourous
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [30] Visual acuity and contrast sensitivity in patients with neovascular age-related macular degeneration - Results from the Radiation Therapy for Age-Related Macular Degeneration (RAD-) Study
    Bellmann, C
    Unnebrink, K
    Rubin, GS
    Miller, D
    Holz, FG
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2003, 241 (12) : 968 - 974